Global Alliance For TB Drug Development Receives Pledge of up to $40 Million from USAID

NEW YORK--(BUSINESS WIRE)--The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership leading the development of new and affordable tuberculosis (TB) drugs, announced today a new grant and pledge of up to $40 million over the next five years from the United States Agency for International Development (USAID). The grant will fund the research and development of new drugs to treat drug-susceptible and drug-resistant strains of TB with a focus on late-stage clinical trials for the TB Alliance’s most advanced drug candidates.